Because your child’s fight against Ewing sarcoma should be made easier.
This study is comparing the effectiveness of palbociclib (IBRANCE®) when taken in combination with chemotherapy medicines irinotecan (IRN) and temozolomide (TMZ) versus IRN and TMZ alone for the treatment of Ewing sarcoma.
Who may participate
Joining a clinical trial is an important and personal decision. Your doctor may have mentioned this study to you, or perhaps you found your way here by yourself. Either way, thank you for your interest.
This study may be an option if you or your child
- are between the ages of 2 – 20 years old
- have been diagnosed with recurrent/relapsed Ewing sarcoma
There are other requirements for taking part in this study. The study doctor will explain these to you.
Recurrent/relapsed Ewing sarcoma
2 – 20 years
Male or Female
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If you decide to participate in this study, you or your child will be randomly assigned to receive the study medicine palbociclib in combination with IRN and TMZ, or IRN and TMZ alone. You or your child are twice as likely to receive palbociclib than not, and you will know what treatment you or your child have been assigned to receive.
The study medicines are taken in 21-day treatment cycles. The number of treatment cycles completed will vary for everyone. You or your child may continue receiving treatment for as long as it is of benefit to you.
You will need to attend regular visits so the study team can monitor how you or your child are responding to treatment. These visits will include health assessments, questionnaires, blood samples, ECGs, CT/MRI scans, and DEXA scans (X-rays that measure bone density).
Length of study treatment
21-day treatment cycles
Number of study visits
Long-term follow up
Phone calls or office visit to check in every 2 months for at least 2 years
About Ewing sarcoma
Recurrent or relapsed Ewing sarcoma is a rare type of bone and soft tissue cancer that either does not improve from treatment or improves only for a limited time. Ewing sarcoma can occur at any age, but it is most common in children and teenagers. Unfortunately, current treatment options for recurrent/relapsed Ewing sarcoma are limited and may not work for everyone. Doctors are working to find better treatment options for people with Ewing sarcoma.
About Ewing sarcoma
Frequently asked questions
Time in the study will vary for everyone and depends on how your cancer (or your child’s cancer) is responding to the treatment. Participants may continue to receive treatment in the study for as long as it is benefiting them. After completing treatment, you or your child will need to check in with the study team about every 2 months for at least 2 years.
You or your child can choose to leave the study at any time, for any reason. Choosing to leave the study will not affect your Ewing sarcoma treatment or future medical care. We encourage you to speak with your oncologist about all available treatment options.
The study medicines are taken in 21-day cycles. The study medicine palbociclib (IBRANCE®) is taken at home by mouth once a day for the first 14 days of each treatment cycle. The chemotherapies IRN and TMZ will be given by staff at the study site for the first 5 days of every treatment cycle.
All medicines have the potential to cause unwanted side effects. The study doctor will discuss the possible risks and benefits of participating in this study with you before you or your child choose to enroll. You can choose to leave the study at any time.